In the first phase I trial using dual CD33-CLL-1 CAR-T cells on 9 R/R AML patients, a 4-week evaluation reported an interesting MRD negative rate of 78%, using flow cytometry, with six patients proceeding to ASCT. This evidence concerns the gene CD33 and acute myeloid leukemia.